Literature DB >> 22281893

Autoantibodies in scleroderma and their association with the clinical profile of the disease. A study of 66 patients from southern Brazil.

Thelma Larocca Skare1, Adriano Erlon Fonseca, Alan Campos Luciano, Pedro Ming Azevedo.   

Abstract

BACKGROUND: Scleroderma is a fairly rare connective tissue disease whose autoantibody profile is associated with different clinical manifestations. The prevalence of autoantibodies in scleroderma is influenced by race and genetics.
OBJECTIVE: To study the prevalence of anti-Scl-70, anti-centromere (ACA) and anti-U1-RNP antibodies in patients with scleroderma in southern Brazil and verify their association with clinical manifestations of the disease.
METHODS: A retrospective study involving 66 patients with scleroderma for the presence of anti-Scl-70, anti-centromere and anti-U1-RNP and of clinical manifestations such as Raynaud's phenomenon, digital micro scars, digital necrosis, telangiectasias, calcinosis, pulmonary fibrosis, pleuritis, pericarditis, cardiomyopathy, arthralgia and arthritis, skin sclerosis, joint contractures, tendon friction rubs, pulmonary hypertension, esophageal disorders and renal crisis.
RESULTS: The prevalence of anti-Scl-70 was 17.8% , that of ACA was 33.3% and the prevalence of U1 RNP was 11.8%. Anti-Scl-70 was associated with the diffuse form of the disease (p = 0.015), presence of cardiomyopathies (p = 0.016) and digital micro scars (p = 0.05). Anti-centromere was more common in the limited form, although it was not statistically significant, and had a protective role associated with cardiomyopathies (p = 0.005). Anti-U1-RNP was more common in the overlap forms (p = 0.0004).
CONCLUSION: The prevalence and profile of clinical associations of autoantibodies in Brazilian patients with scleroderma are similar to those found in the literature.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22281893     DOI: 10.1590/s0365-05962011000600003

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  9 in total

1.  Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?

Authors:  Ramya Janardana; Aswin M Nair; Ajit K Surin; John Anthony Jude Prakash; Mahasampath Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2019-07-15       Impact factor: 2.980

2.  The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters.

Authors:  J N Kimmel; D A Carlson; M Hinchcliff; M A Carns; K A Aren; J Lee; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2016-02-27       Impact factor: 3.598

3.  Clinical, biochemical, and radiological characterization of the calcinosis in a cohort of Mexican patients with systemic sclerosis.

Authors:  María Pilar Cruz-Domínguez; Grettel García-Collinot; Miguel A Saavedra; Gabriela Medina; Rosa Angélica Carranza-Muleiro; Olga Lidia Vera-Lastra; Luis J Jara
Journal:  Clin Rheumatol       Date:  2016-10-07       Impact factor: 2.980

4.  Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.

Authors:  Yannick Allanore; Farhad Gharibdoost; Ahmad Reza Jamshidi; Ali Javinani; Jérôme Avouac; Elnaz Rastkar; Sadid Hooshmandi; Hoda Kavosi
Journal:  J Scleroderma Relat Disord       Date:  2018-11-20

5.  Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.

Authors:  Pia Moinzadeh; Elisabeth Aberer; Keihan Ahmadi-Simab; Norbert Blank; Joerg H W Distler; Gerhard Fierlbeck; Ekkehard Genth; Claudia Guenther; Ruediger Hein; Joerg Henes; Lena Herich; Ilka Herrgott; Ina Koetter; Alexander Kreuter; Thomas Krieg; Kathrin Kuhr; Hanns-Martin Lorenz; Florian Meier; Inga Melchers; Hartwig Mensing; Ulf Mueller-Ladner; Christiane Pfeiffer; Gabriela Riemekasten; Miklós Sárdy; Marc Schmalzing; Cord Sunderkoetter; Laura Susok; Ingo H Tarner; Peter Vaith; Margitta Worm; Gottfried Wozel; Gabriele Zeidler; Nicolas Hunzelmann
Journal:  Ann Rheum Dis       Date:  2014-01-03       Impact factor: 19.103

6.  Clinical and autoimmune profile of scleroderma patients from Western India.

Authors:  Vandana Pradhan; Anjali Rajadhyaksha; Milind Nadkar; Pallavi Pandit; Prathamesh Surve; Maxime Lecerf; Jagadeesh Bayry; Srinivas Kaveri; Kanjaksha Ghosh
Journal:  Int J Rheumatol       Date:  2014-10-19

7.  Systemic Sclerosis in Zimbabwe: Autoantibody Biomarkers, Clinical, and Laboratory Correlates.

Authors:  Elopy N Sibanda; Yvonne Dube; Mazvita Chakawa; Takafira Mduluza; Francisca Mutapi
Journal:  Front Immunol       Date:  2021-11-09       Impact factor: 7.561

8.  Characteristics of patients with systemic sclerosis living in Qatar.

Authors:  Fiaz Alam; Hani Malallah Abdulaziz; Irfan Ul Haq; Salah Mohamed Mahdy; Abdul Rahim Mohammed Siam; Prem Chandra; Samar Al Emadi
Journal:  Qatar Med J       Date:  2019-12-24

Review 9.  Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment.

Authors:  Shirin Assar; Hosna Khazaei; Maryam Naseri; Fardous El-Senduny; Saeideh Momtaz; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  J Immunol Res       Date:  2021-06-24       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.